Primecap Management Co. CA Invests $94.92 Million in Revvity Inc. $RVTY

Primecap Management Co. CA acquired a new stake in Revvity Inc. (NYSE:RVTY) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 853,150 shares of the company’s stock, valued at approximately $94,921,000.

A number of other institutional investors also recently modified their holdings of RVTY. Canada Pension Plan Investment Board bought a new position in Revvity during the second quarter worth $656,000. Legal & General Group Plc acquired a new position in shares of Revvity during the second quarter valued at about $31,388,000. The Manufacturers Life Insurance Company acquired a new position in shares of Revvity during the second quarter valued at about $41,048,000. Sone Capital Management LLC bought a new position in shares of Revvity during the 2nd quarter worth about $12,212,000. Finally, Vega Investment Solutions acquired a new stake in shares of Revvity in the 2nd quarter valued at about $1,167,000. Institutional investors and hedge funds own 86.65% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Weiss Ratings raised Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 30th. Barclays increased their price target on Revvity from $95.00 to $105.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. Wall Street Zen downgraded Revvity from a “buy” rating to a “hold” rating in a report on Sunday, August 16th. Wolfe Research initiated coverage on Revvity in a report on Tuesday, June 2nd. They set a “peer perform” rating for the company. Finally, TD Cowen reiterated a “buy” rating on shares of Revvity in a report on Wednesday, July 15th. Three analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $108.36.

Revvity Trading Up 1.5%

Shares of RVTY stock opened at $124.79 on Wednesday. Revvity Inc. has a 52-week low of $81.22 and a 52-week high of $124.97. The company has a 50-day simple moving average of $112.37 and a two-hundred day simple moving average of $100.63. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80. The company has a market capitalization of $13.93 billion, a price-to-earnings ratio of 59.42, a PEG ratio of 2.24 and a beta of 1.07.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, topping analysts’ consensus estimates of $1.21 by $0.20. The business had revenue of $729.69 million for the quarter, compared to analyst estimates of $702.96 million. Revvity had a return on equity of 8.34% and a net margin of 8.16%.Revvity’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same period last year, the company posted $1.18 earnings per share. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. Research analysts anticipate that Revvity Inc. will post 5.36 EPS for the current fiscal year.

Revvity Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be given a dividend of $0.07 per share. The ex-dividend date is Friday, October 23rd. This represents a $0.28 annualized dividend and a yield of 0.2%. Revvity’s dividend payout ratio is presently 13.33%.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.